Technical Analysis for ORIC - Oric Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New Downtrend | Bearish | -0.31% | |
| Gapped Down | Weakness | -0.31% | |
| Shooting Star Candlestick | Bearish | -0.42% | |
| New Uptrend | Bullish | -0.42% | |
| Earnings Movers | Other | -0.42% | |
| Multiple of Ten Bearish | Other | -0.42% | |
| New Downtrend | Bearish | 2.13% | |
| 20 DMA Support | Bullish | 2.13% | |
| 200 DMA Support | Bullish | 2.13% | |
| Earnings Movers | Other | 2.13% |
| Alert | Time |
|---|---|
| Up 2% | about 1 hour ago |
| Up 1% | about 2 hours ago |
| 60 Minute Opening Range Breakout | about 2 hours ago |
| Gap Down Closed | 1 day ago |
| Reversed from Down | 1 day ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/06/2024
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Immunotherapy Cancer Treatment Treatment Of Cancer Oncology Chemotherapy Antineoplastic Drugs Occupational Safety And Health Precision Medicine Specialty Drugs Cancer Therapeutics Cd73
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Immunotherapy Cancer Treatment Treatment Of Cancer Oncology Chemotherapy Antineoplastic Drugs Occupational Safety And Health Precision Medicine Specialty Drugs Cancer Therapeutics Cd73
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 16.63 |
| 52 Week Low | 4.91 |
| Average Volume | 618,154 |
| 200-Day Moving Average | 9.25 |
| 50-Day Moving Average | 11.80 |
| 20-Day Moving Average | 9.14 |
| 10-Day Moving Average | 8.99 |
| Average True Range | 0.67 |
| RSI (14) | 46.24 |
| ADX | 25.43 |
| +DI | 23.48 |
| -DI | 23.68 |
| Chandelier Exit (Long, 3 ATRs) | 8.91 |
| Chandelier Exit (Short, 3 ATRs) | 9.64 |
| Upper Bollinger Bands | 10.45 |
| Lower Bollinger Band | 7.83 |
| Percent B (%b) | 0.68 |
| BandWidth | 28.73 |
| MACD Line | -0.55 |
| MACD Signal Line | -0.81 |
| MACD Histogram | 0.2613 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 10.44 | ||||
| Resistance 3 (R3) | 10.45 | 10.17 | 10.30 | ||
| Resistance 2 (R2) | 10.17 | 9.96 | 10.17 | 10.25 | |
| Resistance 1 (R1) | 9.89 | 9.83 | 10.03 | 9.88 | 10.21 |
| Pivot Point | 9.61 | 9.61 | 9.69 | 9.61 | 9.61 |
| Support 1 (S1) | 9.33 | 9.40 | 9.47 | 9.32 | 8.99 |
| Support 2 (S2) | 9.05 | 9.27 | 9.05 | 8.95 | |
| Support 3 (S3) | 8.77 | 9.05 | 8.90 | ||
| Support 4 (S4) | 8.76 |
